Analysts Project 120% Upside To Dyne Therapeutics, Inc. (DYN)

Recent expert updates see Evercore ISI’s Gavin Clark-Gartner connected December 17, trimming the firm’s terms people connected the banal to $36 from $38, portion maintaining an earlier Outperform rating.

According to TipRanks, the steadfast praised the institution for its functionality and gathering expectations connected metrics specified arsenic information and efficacy. Despite the cut, the revised terms people represents an upside imaginable of implicit 100% from Monday’s close.

Earlier connected December 10, Oppenheimer upgraded the stock’s standing to Outperform and lifted its terms people to $40 from $11 connected December 10, citing the anticipated Phase 3 proceedings readout for rival Avidity’s RNA therapy, del-desiran successful myotonic dystrophy benignant 1, successful the 2nd fractional of 2026.

According to Oppenheimer, different important upside catalyst for Dyne Therapeutics, Inc. (NASDAQ:DYN) this twelvemonth could beryllium the occurrence of its zeleciment basivarsen therapeutic to dainty patients surviving with myotonic dystrophy benignant 1 (DM1). Moreover, the likelihood of the FDA reviewing the company’s campaigner for Duchenne muscular dystrophy (DMD) could besides assistance the banal rally.

Dyne Therapeutics, Inc. (NASDAQ:DYN) is simply a healthcare institution focused connected processing treatments for patients of genetically driven neuromuscular diseases.

While we admit the imaginable of DYN arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 14 Best S&P 500 Stocks to Buy Now and 11 Most Oversold S&P 500 Stocks Heading into 2026

Disclosure: None.